News

PD-1/PD-L1 interaction blocked by antibodies, freeing T cell to kill tumor cell

Time: 2018-10-22 15:00:35

PD-1/PD-L1 interaction blocked by antibodies, freeing T cell to kill tumor cell

www.fn-test.com  2018-10-22

KEYTRUDA (anti-PD-1(Programmed cell death protein 1) antibody) get approval of FDA.
 
KEYTRUDA, Also called Pembrolizumab, is an anti-PD-1(Programmed cell death protein 1) antibody from humanized( from Mouse),  which has been approved by the FDA.
 
KEYTRUDA Could inhibit the PD-1/PD-L1 pathway in the body and helps the body’s immune system fight cancer cells. PD-1/PD-L1 interaction blocked by antibodies, freeing T cell to kill tumor cell.
 
MSI-H and dMMR tumor is a genetic abnormality could cause the Affecting the intracellular DNA repair mechanism, PD-1/PD-L1 antibodies could be used to treat the Head and neck cancer; Hodgkin’s disease; Malignant melanoma; Non-small cell lung cancer.
 
Reference
1. “Pembrolizumab”. AdisInsight. Retrieved 5 November 2016.
Related Products
2. Pembrolizumab (KEYTRUDA) for classical Hodgkin lymphoma, 15 Mar 2017, FDA
 
Fine Test Related Products
EH0252    Human PD-1/PDCD1(Programmed Cell Death Protein 1) ELISA Kit         0.156-10ng/ml
EH2218    Human PDCD4(Programmed cell death protein 4) ELISA Kit          0.312-20ng/ml

  • Previous: No
  • Next: No

Service

Hotline

027-87384275
var cnzz_s_tag=document.createElement('script'); cnzz_s_tag.type='text/javascript'; cnzz_s_tag.async=true; cnzz_s_tag.charset='utf-8'; cnzz_s_tag.src='https://w.cnzz.com/c.php?id=1253658600&async=1'; var root_s=document.getElementsByTagName('script')[0]; root_s.parentNode.insertBefore(cnzz_s_tag,root_s);